EI

249.2

-1.81%↓

SHL.DE

45.38

-1.13%↓

ARGX

581.8

-2.84%↓

PHIA

22.58

-1.27%↓

SRT3

177.15

-0.67%↓

EI

249.2

-1.81%↓

SHL.DE

45.38

-1.13%↓

ARGX

581.8

-2.84%↓

PHIA

22.58

-1.27%↓

SRT3

177.15

-0.67%↓

EI

249.2

-1.81%↓

SHL.DE

45.38

-1.13%↓

ARGX

581.8

-2.84%↓

PHIA

22.58

-1.27%↓

SRT3

177.15

-0.67%↓

EI

249.2

-1.81%↓

SHL.DE

45.38

-1.13%↓

ARGX

581.8

-2.84%↓

PHIA

22.58

-1.27%↓

SRT3

177.15

-0.67%↓

EI

249.2

-1.81%↓

SHL.DE

45.38

-1.13%↓

ARGX

581.8

-2.84%↓

PHIA

22.58

-1.27%↓

SRT3

177.15

-0.67%↓

Search

Sanofi SA

Open

SectorGezondheidszorg

80.08 -2.66

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

79.92

Max

82.52

Belangrijke statistieken

By Trading Economics

Inkomsten

3.9B

5.8B

Verkoop

11B

21B

K/W

Sectorgemiddelde

15.922

34.393

EPS

1.59

Dividendrendement

4.88

Winstmarge

27.234

Werknemers

82,878

EBITDA

2.2B

2.8B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+31.89% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.88%

2.54%

Volgende Winsten

24 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.1B

100B

Vorige openingsprijs

82.74

Vorige sluitingsprijs

80.08

Nieuwssentiment

By Acuity

37%

63%

123 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Sanofi SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 10:06 UTC

Belangrijke Marktbewegers

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 jul 2025, 06:00 UTC

Winsten

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30 jul 2025, 10:20 UTC

Winsten

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

30 jul 2025, 05:31 UTC

Winsten

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

6 aug 2025, 05:02 UTC

Acquisities, Fusies, Overnames

Sanofi Completes the Acquisition of Vigil Neuroscience

6 aug 2025, 05:00 UTC

Acquisities, Fusies, Overnames

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 aug 2025, 13:16 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 12:40 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 jul 2025, 08:15 UTC

Marktinformatie
Winsten

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 jul 2025, 05:56 UTC

Marktinformatie
Winsten

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 jul 2025, 05:30 UTC

Winsten

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 jul 2025, 05:30 UTC

Winsten

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 jul 2025, 05:30 UTC

Winsten

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Business Operating Profit EUR2.46B

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Adj EPS EUR1.59

31 jul 2025, 05:30 UTC

Winsten

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 jul 2025, 05:30 UTC

Winsten

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Net Pft EUR3.94B

31 jul 2025, 05:30 UTC

Winsten

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31 jul 2025, 05:30 UTC

Winsten

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31 jul 2025, 05:30 UTC

Winsten

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Sales EUR9.99B

31 jul 2025, 05:30 UTC

Winsten

Sanofi Backs 2025 EPS Adj View

31 jul 2025, 05:30 UTC

Winsten

Sanofi Narrows 2025 Sales View

31 jul 2025, 05:30 UTC

Winsten

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

30 jul 2025, 07:48 UTC

Marktinformatie
Winsten

Santander Results Get Lukewarm Reaction -- Market Talk

30 jul 2025, 06:41 UTC

Marktinformatie
Winsten

Santander's Strategic Investments in Focus -- Market Talk

30 jul 2025, 04:52 UTC

Winsten

Santander End-2Q CET1 Ratio 13%

Peer Vergelijking

Prijswijziging

Sanofi SA Prognose

Koersdoel

By TipRanks

31.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 108.192 EUR  31.89%

Hoogste 123.956 EUR

Laagste 89.968 EUR

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sanofi SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

9

Buy

5

Hold

0

Sell

Technische score

By Trading Central

91.3 / 96.1Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

123 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.